AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05124275
Drug: Pilocarpine Ophthalmic Topical Cream, Dose 3
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pilocarpine Ophthalmic Topical Cream, Dose 3
Trial: NCT05207761
Drug: D565
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Q.D. in both eye
Trial: NCT05207761
Drug: D930
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T.I.D in both eye
Trial: NCT05676710
Drug: Linperlisib
RxNorm normalized name: Linperlisib
DrugBank: Linperlisib (DB17235)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated PI3K activity in T-LGL likely plays an important role in the ability of the pathologic cells to avoid homeostatic apoptosis, since inhibition of this pathway leads to apoptosis in the population of cells harboring the pathologic clone. More importantly, the activity of this pathway may represent a kind of Achilles heel for T-LGL in that PI3K inhibitors alone are quite effective at inducing spontaneous apoptosis in the clonal CTLs after a short incubation.
Trial: NCT04800315
Drug: CC-93538
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dosages on specified days
Trial: NCT04725682
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single dose of 1 mg capsule per period
Trial: NCT05813327
Drug: ADI PEG20
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ADI-PEG 20 will be given on an outpatient basis at a dose of 36 mg/m\^2 via intramuscular injection into either the deltoid or gluteal muscle.
Trial: NCT05813327
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide will be administered intravenously per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
Trial: NCT05813327
Drug: Mesna
RxNorm normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesna will be administered for supportive care either intravenously or by mouth per package insert and institutional practice on Days 1 through 5 of all 3 cycles.
Trial: NCT06746519
Drug: BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The starting dose cohort(200mg BID N104) combined Intensive Chemotherapyor Venetoclax/Azacitidine. Each treatment cycle is anticipated to be 28 days in length, although cycle delays may be made due to delayed count recovery.
Trial: NCT05355805
Drug: Izokibep
RxNorm normalized name: Izokibep
DrugBank: Izokibep (DB19081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic: IL-17A inhibitor~Form: Solution for injection~Route of administration: Subcutaneous (SC)
Trial: NCT05355805
Drug: Placebo to izokibep
DrugBank: Izokibep (DB19081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form: Solution for injection~Route of administration: Subcutaneous (SC)
Trial: NCT06675578
Drug: Tulsi gel
RxNorm normalized name: Tulsi Top
DrugBank: Ocimum tenuiflorum top (DB14273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After scaling and root debridement, 4% of Tulsi gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
Trial: NCT06675578
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After scaling and root debridement, 1% of Chlorhexidine gel will be injected in to the sulcus until it over flooded, at base line, then after one month.
Trial: NCT06657300
Drug: PRP
RxNorm normalized name: PRP
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 1 ml PRP (Vacusera) was injected into the 1st CMC joint of the first group. Injection was performed under USG (Clarius; L7 HD Linear Ultrasound Scanner) guidance by the same physician after skin sterilization.
Trial: NCT06674226
Drug: Ciprofol
RxNorm normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25mg/kg for anesthesia induction ＋0.25\~1.5 mg/kg/h for maintenance
Trial: NCT06674226
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.0mg/kg for induction ＋1 \~ 6mg/kg/h for maintenace
Trial: NCT05295433
Drug: mRNA-3705
RxNorm normalized name: mRNA-3705
DrugBank: mRNA-3705 (DB17668)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A sterile liquid for injection
Trial: NCT05890105
Drug: PF-07853578
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.
Trial: NCT06656429
Drug: Transforaminal Epidural Steroid Injections
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transforaminal Epidural Steroid Injections
Trial: NCT05466838
Drug: PERT at discharge
RxNorm normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose 50,000 units lipase per meal with 3 meals planned per day and 25,000 units of lipase per snack with 2 snacks planned per day. Dose escalation 100,000 units lipase with meals and 50,000 units with snacks.
Trial: NCT05522517
Drug: Cosentyx
RxNorm normalized name: Cosentyx
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cosentyx injection will be administered subcutaneously.
Trial: NCT05522517
Drug: Candin
RxNorm normalized name: Candin
DrugBank: Candida albicans (DB10429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candin will be administered interadermally along with NaCl solution.
Trial: NCT06657209
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 weeks started at 2.5mg/week and increased to 5mg/week dose
Trial: NCT06657209
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 weeks at a 45mg/day dose
Trial: NCT05134857
Drug: Zonisamide
RxNorm normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The ZON will be supplied in 100 mg capsules and deposited directly into the TAD device by research staff every 2 weeks. All participants will be told to take 100 mg/day for the first three weeks (Week 1-2 single-blind, placebo-only, induction; end of Week 2, active treatment begins) and increasing by 100 mg/day every other week (Week 4: 200 mg/day; Week 6: 300 mg/day; Week 8: 400 mg/day) up to the target dose of 500 mg/day by Week 10. The participants will be maintained on this dose through Week 14 of active treatment and then tapered off ZON (2 weeks). This dosing schedule is consistent with best practices for ZON. All TAD devices will only dispense the prescribed medication between 4pm and 11pm each night. Participants will be instructed to take the medication at or near bedtime.
Trial: NCT06479603
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subjects will receive oral nintedanib. It will be prescribed to be taken after meals with 12 hrs gap between doses. The drug will be started at a dose of 100 mg twice daily. After 2 weeks, the dose will be titrated up to 150 mg twice daily, which will be continued till the end of 52 weeks. The standard-of-care immunosuppressive treatment will be continued along with the study drug (nintedanib). In case of intolerance to the 300 mg/day dose of nintedanib, the dose will be reduced to 100 mg twice daily. In case of severe adverse effects, the drug will be stopped and reintroduced after a period of up to 1-4 weeks. A dose of 100 mg twice daily will be started and continued. One attempt to titrate the dose up to 150 mg twice daily will be permitted.
Trial: NCT05631028
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine is the most popular adjuvant to anesthesia. Groups was grouped according to different preadministered doses of dexmedetomidine. This allows a more comprehensive assessment of remimazolam under different use. Three groups were set separately, and Group A, Group B, and Group C correspond to 0,0.5, and 1 μg/kg at first 10 mins , respectively.
Trial: NCT05631028
Drug: Remimazolam tosilate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam tosilate has a short clinical time and a lack of combination with dexmedetomidine for dual-lumen endotracheal intubation. The optimal use dose of Remimazolam tosilate was explored separately from different dexmedetomidine doses.
Trial: NCT06617481
Drug: 18F-rhPSMA-7.3 (Posluma)
DrugBank: Flotufolastat F-18 (DB17851)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET Scan using Posluma for detection of early recurrence of prostate cancer.
Trial: NCT04561180
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The comparator, Administered as an Intravenous infusion
Trial: NCT05006170
Drug: DTG DT 20 mg
RxNorm normalized name: L-DT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Give 2 tabs of MYLTEGA DT (10mg) PO once daily
Trial: NCT05006170
Drug: DTG DT 25 mg
RxNorm normalized name: L-DT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Give 2.5 tabs of MYLTEGA DT (10mg) PO once daily
Trial: NCT04840667
Drug: REPLAGAL
DrugBank: Agalsidase alfa (DB15874)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Participants will receive REPLAGAL 0.2 mg/kg body weight of IV infusion for 104 weeks.
Trial: NCT06060301
Drug: sulfasalazine 500 MG
RxNorm normalized name: sulfasalazine 500 MG
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will use topical corticosteroids in addition to topical sulfasalazine 4 times per day.
Trial: NCT06494878
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75-100 mg taken once daily by mouth.
Trial: NCT06746753
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: randomized to receive Angiotensin II continuous infusion for up to 48 hours
Trial: NCT06607029
Drug: the opioid-free anesthesia group
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will be administered with an opioid-free strategy during surgery. The investigator will use esketamine, dexmetopidine, and local anesthesia to control perioperative pain.
Trial: NCT03423355
Drug: Dapagliflozin (Forxiga®)
RxNorm normalized name: dapagliflozin Oral Tablet [Farxiga]
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg p.o. daily
Trial: NCT03423355
Drug: Hydrochlorothiazide 25 mg
RxNorm normalized name: hydrochlorothiazide 25 MG
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg p.o. daily
Trial: NCT03423355
Drug: Placebo matching Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Placebo matching Dapagliflozin p.o. daily
Trial: NCT05127486
Drug: Galcanezumab
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC.
Trial: NCT05127486
Drug: Rimegepant
RxNorm normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05402384
Drug: AVTX-801
DrugBank: VTX-801 (DB17646)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical grade D-galactose~dosage:2.0 g/kg/day
Trial: NCT06642480
Drug: Post Operative Analgesia
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administering 100 mg of intravenous tramadol 30 minutes before the operation is completed
Trial: NCT06642480
Drug: Post Operative Analgesia
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAS of 63 patients was determined by injecting tramadol at a dose of 100 mg 30 minutes before the operation was completed. It was observed in the recovery room at 30, 60, and 120 minutes.
Trial: NCT06159478
Drug: Binimetinib 15 MG
RxNorm normalized name: binimetinib 15 MG
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Binimetinib 45mg is orally administered twice daily.
Trial: NCT05113940
Drug: PF-07258669
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days
Trial: NCT05113940
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669
Trial: NCT05789992
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol (Random:3-5ug/ml)
Trial: NCT05211167
Drug: Human Erythropoiesis Injection (CHO cell)
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human Erythropoiesis Injection (CHO cell) is a recombinant human erythropoietin with the same biological effects as natural erythropoietin
Trial: NCT05211167
Drug: Recombinant Erythropoiesis Stimulating Protein Injection(CHO cell)
RxNorm normalized name: Granulocyte colony stimulating factor 3 (CHO cell derived)
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rESP is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
Trial: NCT04912167
Drug: Sacubitril-Valsartan
RxNorm normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After initiation of the treatment of sacubitril/valsartan, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (24/26 mg, 49/51 mg and 97/103 mg, twice daily)
Trial: NCT04912167
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After initiation of the treatment of enalapril, the dose of the medicine will be titrated to a target level based on the systolic blood pressure of the patients. (2.5 mg, 5 mg, and 10 mg,twice daily)
Trial: NCT04912167
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients who were previously treated with ACEI and receiving the last dose of that agent during the last 36 hours prior to randomization, Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day was used.
Trial: NCT04714112
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous administration of dexamethasone at different time for the duration of ISB with 0.5% ropivacaine
Trial: NCT04147949
Drug: AV-101
RxNorm normalized name: AV-101
DrugBank: AV-101 (DB12878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules taken twice daily for 14 days
Trial: NCT05412706
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive Niraparib 200-300 mg orally as an individualized weight and platelet-based, flat-fixed, continuous daily dose.~Niraparib will be administered orally once daily in 28-day cycles.
Trial: NCT04808687
Drug: Nab paclitaxel and S-1
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-Paclitaxel: 125 mg/m2 d1, 8, during each 3-week cycle. S-1: Body surface area \< 1.25 m2, 40 mg bid; Body surface area ≥ 1.25 m2 \< 1.50 m2, 50 mg bid; Body surface area ≥1.5 m2, 60 mg bid, d1-14;during each 3-week cycle.
Trial: NCT04871815
Drug: sodium pyruvate nasal spray
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will use a sodium pyruvate nasal spray 3x daily for 7 days.
Trial: NCT05510986
Drug: Oxycodone Hydrochloride group
RxNorm normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
Trial: NCT05229965
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Trial: NCT05229965
Drug: Paracetamol caféine
RxNorm normalized name: Caféine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 21 pills will be provided with a preconised dose of 1 pill 3 times per day over 7 days period
Trial: NCT04007276
Drug: brimonidine tartrate ophthalmic solution 0.025%
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of brimonidine tartrate ophthalmic solution 0.025% applied as an eye drop to the eye surface.
Trial: NCT04751500
Drug: Antibiotic
RxNorm normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Giving antibiotics to reduce any inflammation/infection caused by the retained pregnancy tissue allowing it to pass by itself
Trial: NCT00040157
Drug: ACH126-443 (Beta-L-Fd4C)
RxNorm normalized name: Beta-l-thymidine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04512261
Drug: Tucatinib
RxNorm normalized name: Tucatinib
DrugBank: Tucatinib (DB11652)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Initial dosage of trial treatment for tucatinib will be given as 300 mg (dispensed as 2 x 150 mg tablets) orally twice a day for Days 1 - 21 of each 3-week cycle during the treatment period.
Trial: NCT04512261
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial dosage of trial treatment for pembrolizumab will be given as 200 mg by intravenous infusion every 3 weeks on Day 1 of each 3-week cycle during the treatment period. Pembrolizumab will be administered for a maximum of 35 doses.
Trial: NCT04512261
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial dosage of trial treatment for trastuzumab will be given as 8 mg/kg by intravenous (IV) infusion once on Day 1 of Cycle 1, and 6 mg/kg by IV every 3 weeks on Day 1 of each 3-week cycle starting on Cycle 2 during the treatment period.
Trial: NCT04615871
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: semaglutide 0.25 mg s.c. on Day 0 after randomization, then semaglutide 0.5 mg s.c. on Day 7, Day 14 and Day 21
Trial: NCT05899725
Drug: Corticosteroids and Ruxolitinib
RxNorm normalized name: abiraterone and corticosteroids
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initial dosage of corticosteroids is no less than predinisone 1mg/kg/d or other corticosteroids with equal equivalence, add-on oral Ruxolitinib 5mg twice a day for 2 weeks, following with Ruxolitinib
Trial: NCT06559436
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,
Trial: NCT04723030
Drug: carleilizumab+apathy mesylate+radiotherapy+paclitaxel (albumin-bound)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Carrilizumab ：200mg,q2w; Apatinib :250mg,d1; which is taken continuously for 5 days and stopped for 2 days, and stopped for 2 weeks after radiotherapy.~Taxol :125mg/m2,q2w; Gemcitabine :1000mg/m2, q2w; cisplatin :25mg/m2, q2w; Radiotherapy:30Gy, divided into five times and completed within one week.
Trial: NCT05091138
Drug: Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty
RxNorm normalized name: Aldex AN
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
Trial: NCT05091138
Drug: Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty
RxNorm normalized name: Aldex AN
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
Trial: NCT05593432
Drug: Ruxolitinib cream
RxNorm normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.